Екатерина Умнякова - Как работает иммунитет [litres]

Hamishehkar H., Ranjdoost F., Asgharian P., Mahmoodpoor A., Sanaie S. Vitamins, Are They Safe? // Adv Pharm Bull, 2016. Vol. 6, № 4. P. 467–477.

Hemilä H.Vitamin C and the common cold // British Journal of Nutrition. 1992. Vol. 67. P. 3–16.

Cowan D.W., Dieh H.S., Baker A.B. Vitamins for the prevention of colds // JAMA. 1942. Vol.120, № 16, P. 1268–1271.

Hemilä H., Chalker E. VitaminCforpreventingandtreatingthecommoncold // CochraneDatabaseSystRev. 2013. № 1. CD000980.

Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., Ross C., Arnold A., Sleight P., Probstfield J., Dagenais G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial // JAMA. 2005. Vol. 293, № 11. P. 1338–1347; Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases // Cochrane Database Syst Rev. 2012. № 3. CD007176.

Martínez M.E., Jacobs E.T., Baron J.A., Marshall J.R., Byers T. Dietary supplements and cancer prevention: balancing potential benefits against proven harms // J Natl Cancer Inst. 2012. Vol. 104, № 10. P. 732–739; Klein E.A., Thompson I.M., Tangen C.M., et al. Vitamin E and the risk of prostate cancer. The Selenium and vitamin E cancer prevention trial (SELECT) // JAMA. 2011. Vol. 306, № 14. P. 1549–1556; Miller E.R. 3rd, Pastor-Barriuso R., Dala D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality //Ann Intern Med. 2005. Vol. 142, № 1, P. 37–46; Lawson K.A., Wright M.E., Subar A., Mouw T., Hollenbeck A., Schatzkin A., Leitzmann M.F.Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study // J Natl Cancer Inst. 2007. Vol. 99, № 10, P. 754–764; Park S-Y., Murphy S.P., Wilkens L.R., Henderson B.E., Kolonel L.N. Multivitamin use and the risk of mortality and cancer incidence the multiethnic cohort study // Am J Epidemiol. 2011. Vol.173, № 8. P. 906–914.

Randall K.L. Rituximabinautoimmunediseases // AustPrescr. 2016. Vol. 39, № 4. P. 131–134; Vital E.M., Emery P. Abatacept in the treatment of rheumatoid arthritis // Ther Clin Risk Manag. 2006. Vol. 2, № 4. P. 365–375; Dubey A.K., Handu S.S., Dubey S., Sharma P., Sharma K.K., Ahmed Q.M. Belimumab: First targeted biological treatment for systemic lupus erythematosus // J Pharmacol Pharmacother. 2011. Vol. 2, № 4, P.317–319.

Quach H., Ritchie D., Stewart A.K., Neeson P., Harrison S., Smyth M.J., Prince H.M. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma // Leukemia. 2010. Vol. 24, № 1. P. 22–32; Andhavarapu S., Roy V. Immunomodulatory drugs in multiple myeloma // Expert Review of Hematology. 2013. Vol. 6, № 1. P. 69–82; Sedlarikova L., Kubiczkova L., Sevcikova S., Hajek R. (October 2012). Mechanism of immunomodulatory drugs in multiple myeloma // Leukemia Research. 2012. Vol. 36, № 10. P. 1218–1224.

Chang X.B., Stewart A.K. What is the functional role of the thalidomide binding protein cereblon? // International Journal of Biochemistry and molecular biology. 2011. Vol. 2, № 3. P. 287–294.

Baldo B.A. Side effects of cytokines approved for therapy. // Drug Saf. 2014. Vol. 37. P. 921–943.

Baldo B.A. Side effects of cytokines approved for therapy. // Drug Saf. 2014. Vol. 37. P. 921–943.

Ribes S., Ebert S., Czesnik D., Regen T., Zeug A., Bukowski S., Mildner A., Eiffert H., Hanisch U.-K., Hammerschmidt S. Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. // Infect Immun. 2009. Vol.77. P. 557–564.; Ribes S., Ebert S., Regen T., Agarwal A., Tauber S.C., Czesnik D., Spreer A., Bunkowski S., Eiffert H., Hanisch U-K. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. // Infect Immun. 2010. Vol. 78. P. 865–871.

Louveau A.,Smirnov I., Keyes T.J., Eccles J.D., Rouhani S.J., Peske J.D., Derecki N.C., Castle D., Mandell J.W., Lee K.S., Harris T.H., Kipnis J. Structural and functional features of central nervous system lymphatic vessels. // Nature. 2015. Vol. 523. P. 337–341.

AbsintaM., HaS.-K., NairG., SatiP.,1 LucianoN.J., PalisocM., LouveauA., ZaghloulK.A., PittalugaS., KipnisJ., ReichD.S. HumanandnonhumanprimatemeningesharborlymphaticvesselsthatcanbevisualizednoninvasivelybyMRI. // eLife. 2017. Vol. 6. Articlee29738.

Baruch K., Rosenzweig N., Kertser A., Deczkowska A., Sharif A.M., Spinrad A., Tsitsou-Kampeli A., Sarel A., Cahalon L., Schwartz M. Breaking immune tolerance by targeting Foxp3+ regulatory T cells mitigates Alzheimer’s disease pathology. // Nat Commun. 2015. Vol. 6. Article 7967.

Filiano A.J., Xu Y., Tustison N.J., Marsh R.L., Baker W., Smirnov I., Overall C.C., Gadani S.P., Turner S.D., Weng Z., Peerzade S.N., Chen H., Lee K.S., Scott M.M., Beenhakker M.P., Litvak V., Kipnis J. // Nature. 2016. Vol. 535. P. 425–429.

Rothwell N.J., Luheshi G.N.Interleukin 1 in the brain: biology, pathology and therapeutic target. // Trends Neurosci. 2000. Vol. 23, № 12. P. 618–625.

Presumey J., Bialas A.R., Carroll M.C. Complement system in neural synapse elimination in development and disease. // Adv Immunol. 2017. Vol.135. P. 53–79.

Cebrián C., Loike J.D., Sulzer D. Neuronal MHC–I expression and its implications in synaptic function, axonal regeneration and Parkinson’s and other brain diseases. // Front Neuroanat. 2014. Vol. 8. Article 114.

Cannon W.B. Bodily changes in pain, hunger, fear and rage. New York: Appleton and Co., 1915; Quick J.C., Spielberger C.D. Walter Bradford Cannon: pioneer of stress research, international journal of stress management. // International Journal of Stress Management. 1994. Volume 1, № 2. P. 141–143.

SelyeH. Stressanddisease. // TheLaryngoscope. 1955. Vol. 65, № 7. P. 500–514.

Selye, H. (1976). Stress in health and disease. Boston: Butterworths. – 1300 pp.

Cosentino M, Kustrimovic N & F Marino, Endogenous catecholamines in immune cells: Discovery, functions and clinical potential as therapeutic targets (October 5, 2013). In Brain Immune: Trends in Neuroendocrine Immunology. Retrieved April 27, 2017; Cosentino M, Marino F. Nerve-driven immunity: noradrenaline and adrenaline. In: Levite M. (ed.), Nerve-driven-immunity – Neurotransmitters and neuropeptides in the immune system. Springer-Verlag/Wien, 2012: pp. 47–96.

Coutinho A.E., Chapman K.E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. // Mol Cell Endocrinol. 2011. Vol. 335, № 31. P. 2–13.

Alhola P., Polo-Kantola P. Sleep deprivation: Impact on cognitive performance. // Neuropsychiatr Dis Treat. 2007. Vol. 3, № 5. P. 553–567.

Plog B.A., Nedergaard M. The glymphatic system in central nervous system health and disease: past, present, and future. // Annu Rev Pathol. 2018. Vol.13. P. 379–394.

Prather A.A.; Leung C.W. Association of insufficient sleep with respiratory infection among adults in the United States. // JAMA Intern Med. 2016. Vol. 176, № 6. P. 850–852.

Chandra R.K. Nutrition and the immune system: an introduction. // Am J Clin Nutr. 1997. Vol. 66, № 2. P. 460S-463S.

Bourke C.D., Berkley J.A., Prendergast A.J. Immune dysfunction as a cause and consequence of malnutrition. // Trends Immunol. 2016. Vol. 37, № 6. P. 386–398.

Calder P.C., Jackson A.A. Undernutrition, infection and immune function. // Nutr Res Rev. 2000. Vol. 13, № 1. P. 3–29; Chandra R.K. 1990 McCollum Award lecture. Nutrition and immunity: lessons from the past and new insights into the future. // Am J Clin Nutr. 1991 Vol. 53, № 5. P. 1087–1101.